Kara N Babaian1, Megan M Merrill1, Surena Matin1, Pheroze Tamboli2, Nizar M Tannir3, Eric Jonasch3, Christopher G Wood1, Jose A Karam4. 1. Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. 2. Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. 3. Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. 4. Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: JAKaram@mdanderson.org.
Abstract
PURPOSE: Cytoreductive nephrectomy remains the standard of care for appropriately selected patients with metastatic renal cell carcinoma. Although the role of partial nephrectomy is well accepted in patients with localized disease, limited data are available on partial nephrectomy in the metastatic setting. We identified the indications for and outcomes of partial nephrectomy in the setting of metastatic renal cell carcinoma with particular attention to partial nephrectomy subgroups. MATERIALS AND METHODS: We analyzed data on a consecutive cohort of 33 patients with metastatic renal cell carcinoma who underwent partial nephrectomy at a single institution between 1996 and 2011. Nonparametric statistics were used to compare partial nephrectomy subgroups. Overall survival was estimated using the Kaplan-Meier method and survival functions were compared using the log rank test. RESULTS: At presentation 8 patients had bilateral synchronous renal masses, 20 had a metachronous contralateral renal mass and 5 had a unilateral renal mass. A total of 22 patients (67%) died of disease a median of 27 months postoperatively. Patients who underwent partial nephrectomy for a metachronous contralateral renal mass and a renal mass 4 cm or less had the best overall survival (61 and 42 months, respectively). Median overall survival in patients with vs without metastatic disease at original diagnosis was 27 vs 63 months (p = 0.003). CONCLUSIONS: Our findings suggest that metastasis at the original diagnosis and the timing of presentation of the partial nephrectomy index lesion have an important role in survival. These factors should be considered when determining which patients would benefit from partial nephrectomy in the setting of metastatic renal cell carcinoma.
PURPOSE: Cytoreductive nephrectomy remains the standard of care for appropriately selected patients with metastatic renal cell carcinoma. Although the role of partial nephrectomy is well accepted in patients with localized disease, limited data are available on partial nephrectomy in the metastatic setting. We identified the indications for and outcomes of partial nephrectomy in the setting of metastatic renal cell carcinoma with particular attention to partial nephrectomy subgroups. MATERIALS AND METHODS: We analyzed data on a consecutive cohort of 33 patients with metastatic renal cell carcinoma who underwent partial nephrectomy at a single institution between 1996 and 2011. Nonparametric statistics were used to compare partial nephrectomy subgroups. Overall survival was estimated using the Kaplan-Meier method and survival functions were compared using the log rank test. RESULTS: At presentation 8 patients had bilateral synchronous renal masses, 20 had a metachronous contralateral renal mass and 5 had a unilateral renal mass. A total of 22 patients (67%) died of disease a median of 27 months postoperatively. Patients who underwent partial nephrectomy for a metachronous contralateral renal mass and a renal mass 4 cm or less had the best overall survival (61 and 42 months, respectively). Median overall survival in patients with vs without metastatic disease at original diagnosis was 27 vs 63 months (p = 0.003). CONCLUSIONS: Our findings suggest that metastasis at the original diagnosis and the timing of presentation of the partial nephrectomy index lesion have an important role in survival. These factors should be considered when determining which patients would benefit from partial nephrectomy in the setting of metastatic renal cell carcinoma.
Authors: Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: Georg C Hutterer; Jean-Jacques Patard; Marc Colombel; Arie S Belldegrun; Christian Pfister; Francois Guille; Walter Artibani; Francesco Montorsi; Allan J Pantuck; Pierre I Karakiewicz Journal: Cancer Date: 2007-12-01 Impact factor: 6.860
Authors: Matthew H Hayn; Nicholas J Hellenthal; Stéfanie A Seixas-Mikelus; Ahmed M Mansour; Andrew Stegemann; Abid Hussain; Khurshid A Guru Journal: BJU Int Date: 2010-12-16 Impact factor: 5.588
Authors: Eric C Umbreit; Mark S Shimko; M Adam Childs; Christine M Lohse; John C Cheville; Bradley C Leibovich; Michael L Blute; R Houston Thompson Journal: BJU Int Date: 2011-05-09 Impact factor: 5.588
Authors: Ken-Ryu Han; Allan J Pantuck; Matthew H T Bui; Oleg Shvarts; Danielo G Freitas; Amnon Zisman; Bradley C Leibovich; Frederick J Dorey; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun Journal: Urology Date: 2003-02 Impact factor: 2.649
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Tobias Klatte; Jean-Jacques Patard; Michela de Martino; Karim Bensalah; Gregory Verhoest; Alexandre de la Taille; Clément-Claude Abbou; Ernst Peter Allhoff; Giuseppe Carrieri; Stephen B Riggs; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck Journal: J Urol Date: 2008-03-17 Impact factor: 7.450
Authors: Umberto Capitanio; Laurent Zini; Paul Perrotte; Shahrokh F Shariat; Claudio Jeldres; Philippe Arjane; Daniel Pharand; Hugues Widmer; François Péloquin; Francesco Montorsi; Jean-Jacques Patard; Pierre I Karakiewicz Journal: Urology Date: 2008-09-16 Impact factor: 2.649
Authors: Stephen A Boorjian; Paul L Crispen; Christine M Lohse; Bradley C Leibovich; Michael L Blute Journal: Eur Urol Date: 2008-05-09 Impact factor: 20.096
Authors: Javier Puente Vázquez; T Alonso Gordoa; J Moreno; L Poma; E Diaz Rubio; A Gomez; J Blazquez; J L Gonzalez Larriba Journal: Curr Treat Options Oncol Date: 2015-03